Legal Perspectives on Precision Medicine and Life Science

Anne Kjersti Befring, Associate Professor at the University of Oslo.

Which genetic analyses are we allowed to perform in health care, and which rules apply to patient treatments that involve the use of technology? In this episode, Anne Kjersti and Silvija discuss the matter of making complex questions understandable - understanding that what appears to be simple is often based on complex assessments.

Follow this link to listen to the podcast!


Learnings from the episode

  • Handling biological data
  • Legal instruments
  • Regulations
  • Innovation in health care

This article is from an episode of #Lørn, made in collaboration with LørnTech


Food for Thought

During a pandemic, if we do not think in a different manner, tensions will arise between a traditional view of the law and and what may be a threat to the law. For example, as with the CORONA-Act.

How can we make better use of our resources and streamline the Norwegian health care sector to continue the ongoing development in precision medicine? 

Anne Kjersti Befring

Associate Professor at the Faculty of Law

University of Oslo

+47 958 27 358

Send email

Relevant Projects

Illustration

Classified Variants are Anonymous

I BigMed-prosjektet er det foretatt en vurdering av om fortolkede genetiske varianter er anonyme og hvordan grensen mellom anonyme og personidentifiserbare genetiske opplysninger kan trekkes
Consent Management for Genomics

Consent Management for Genomics

With the increased utilization of genomic sequencing in the clinical context in Norway, practical and ethical issues in the development of the content and process of informed consent (IC) are emerging. Challenges exist in bridging the